Best Practices for the Implementation of Clinical Advances in HR-Positive/HER2-Negative Breast Cancer

Download these slides from an expert-led symposium reviewing updates in oral targeted therapy for HR-positive/HER2-negative breast cancer and implementation in clinical practice.

Allison Butts, PharmD, BCOP Kristina F. Byers, PharmD, BCOP Released: March 30, 2022

In this commentary, we discuss updates on the use of oral targeted therapies for the treatment of HR-positive/HER2-negative early and metastatic breast cancer, adverse event management, and tools for adherence.

Allison Butts, PharmD, BCOP Kristina F. Byers, PharmD, BCOP Released: April 25, 2022

Listen to the experts discuss current and emerging oral targeted therapies for advanced HR+/HER2- breast cancer, adverse event management, and strategies to promote adherence.

Allison Butts, PharmD, BCOP Kristina F. Byers, PharmD, BCOP Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 3, 2022 Expired: No longer available for credit